Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 11/20 | 0.41 |
| ▸ | IGF1R | P08069 | 4/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5081252 | 0.79 | TNK2 (0.42) | TNK2IGF1RPIK3CDPIK3R2PIK3CG | |
| SCHEMBL401938 | 0.79 | TNK2 (0.65) | TNK2IGF1RPIK3CG | |
| SCHEMBL397876 | 0.75 | BTK (0.51) | ABL1 | |
| SCHEMBL397834 | 0.74 | HCK (0.50) | — | |
| Carbamic Acid SCHEMBL4070573 | 0.71 | TNK2 (0.64) | TNK2 | |
| SCHEMBL400980 | 0.68 | TNK2 (0.72) | TNK2 | |
| SCHEMBL400088 | 0.68 | TNK2 (0.77) | TNK2IGF1R | |
| SCHEMBL399626 | 0.68 | TNK2 (0.64) | TNK2IGF1R | |
| SCHEMBL5084882 | 0.68 | IGF1R (0.48) | TNK2IGF1R | |
| Carbamic Acid SCHEMBL19244736 | 0.68 | BTK (0.55) | PIK3CDPIK3CGABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101613-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-01-24 | — | — | US | claimed |
| US-8101613-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325928-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | TNK2 405/4885IGF1R 1/4885PIK3CD 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.